4 Reasons Life Sciences M&A Due Diligence Demands a Purpose-Built AI Platform

Life sciences transactions involve large volumes of highly sensitive information. A single data room can contain thousands of documents spanning intellectual property (IP), regulatory filings, clinical research, environmental assessments and commercialization plans.

To keep mergers and acquisitions (M&A) on track and avoid delays in developing and commercializing potentially life-changing treatments, bankers, lawyers, specialist consultants and corporate teams must review diligence materials quickly and apply their expertise without overlooking critical information.

In my role as Head of Healthcare and Life Sciences, EMEA at SS&C Intralinks, I work closely with dealmakers navigating these challenges. In this video, I explain how DealCentre AI™, powered by Link — our purpose-built AI engine — streamlines time-consuming work across the entire deal life cycle. This helps specialists focus their expertise where it matters most and accelerate execution without compromising security.

1. Life sciences due diligence requires speed, scale and expertise

Unlike industries where diligence centers around contracts and financial statements, life sciences deals involve layers of IP rights, production roadmaps, and regulatory and environmental factors. The volume and complexity of information in the data room makes diligence documentation especially difficult to analyze at scale.

Effective due diligence requires input from a group of subject matter experts (SMEs). Because life sciences deals often involve unproven scientific assets, the stakes are especially high. In most industries, a mistake in diligence is recoverable. In life sciences, it can cause a buyer to abandon the deal.

2. AI gives specialists more capacity to apply their judgment

Many dealmakers are still in the early stages of AI adoption as the technology evolves at an unprecedented pace. Rather than automating judgement, deal teams are using AI to accelerate time-consuming tasks and keep deals moving forward.

By prompting AI tools like Link within DealCentre AI, deal teams can instantly query large volumes of data and documents, allowing them to identify errors sooner, reduce billable hours and direct their expertise to the issues that require human expertise.

Activity reporting and data room analytics in DealCentre AI provide another layer of intelligence during deal execution, helping teams identify the most engaged buyers, monitor deal progress and identify areas that may require attention.

3. Sensitive data must remain protected throughout the process

When executing transactions involving highly sensitive IP and patient data, the security of the AI tools used during diligence is just as important as the efficiency gains they provide. Standalone general-purpose models often require users to upload or transfer information beyond governed systems. Link operates directly within the secure, permission-controlled Intralinks environment dealmakers have trusted for decades.

For firms that want to use approved external AI tools, DealCentre Connect provides a secure model context protocol (MCP) connection to live deal information without requiring documents to be downloaded or exported. Link also operates under a no-train policy, addressing data usage concerns shared by many dealmakers.

4. AI should solve specific problems

Firms are smart to approach AI with some caution, particularly when sensitive information and high-value decisions are involved. To maximize AI’s impact, organizations should begin by identifying the processes consuming the most time and resources.

Built to understand the context behind M&A deals, DealCentre AI is already supporting live transactions in areas such as data room preparation, document summarization, Q&A management and automation, and the redaction of personally identifiable information (PII). These focused applications allow teams to apply AI where it can deliver practical value while maintaining human oversight.

Looking ahead

Life sciences dealmakers are under pressure to evaluate more information than ever without sacrificing rigor or control. General-purpose large language models (LLMs) may help individuals work faster, but complex transactions require AI that understands deal context, operates within established permissions and supports the workflows that move diligence forward.

DealCentre AI brings these capabilities directly into a secure, end-to-end M&A platform, helping teams move through complex diligence with greater speed and confidence. In a sector where access to capital can turn innovation into real-world outcomes, the ability to review complex diligence materials faster and act on critical findings with confidence can give more promising treatments a path forward.

Ready to learn more about how DealCentre AI can help your team? Get in touch with our experts today.